AHA, FAH report documents dramatic rise in US inpatient drug costs

12 October 2016

Inpatient hospital drug costs increased more than 38% per admission between 2013 and 2015, according to a new report from the University of Chicago’s NORC, an independent research institution.

According to the analysis of inpatient drug pricing data from 712 community hospitals and two group purchasing organizations representing more than 1,400 community hospitals, unit price increases occurred for both low- and high-volume drugs and for both branded and generic drugs.

The report comes at a time of much criticized and publicized drug price hike at the pharmacy level, which have led to congressional investigations and hearings.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Today's issue

Company Spotlight





More Features in Pharmaceutical